

1. Last Name, First Name
2. What percentage of your work time is currently spent in each of the following activities? (should add to 100%)
 - a. Research
 - b. Patient care
 - c. Teaching
 - d. Administration
 - e. Other (specify)
3. What percentage of time is currently spent on sickle cell disease research?

Questions about the period when you were a DDCF ICRA grantee:

4. Were you conducting research into SCD before you applied for the DDCF ICRA grant? Yes/no
5. What drew you to the ICRA grant opportunity? (text, 3-5 sentences)
6. How would you categorize the research project along the therapeutic development continuum? Check all that apply.
 - a. Basic research/mechanism of disease
 - b. Drug or device discovery research
 - c. Preclinical laboratory studies
 - d. Phase 1/2 trials
 - e. Phase 3 trial
 - f. Other (specify)

Outcomes from your ICRA grant:

7. In lay terms, what was the major research outcome from your ICRA grant? (text, 4-5 sentences)
8. Did you receive follow-on funding for the ICRA project? yes/no
9. Please specify the granting agency, grant number, title, total costs, and period for each grant. If easier, indicate grants that grew out of the ICRA project in your biosketch and note below to refer to the biosketch.
If you did not receive follow-on funding, list "N/A."
10. Have you published the research supported by your ICRA grant in peer-reviewed journals? yes/no
11. Please list the reference for each ICRA-supported publication. If easier, indicate papers supported by DDCF in your biosketch and note below to refer to the biosketch.
If you did not have ICRA-supported publications, list "N/A."
12. Were you awarded patents and/or licensed technology based on your ICRA project? Yes/no
13. Please specify the patents and licenses.
14. For licensed technology, please share the name of the licensee and, if available, how the license has advanced your invention toward clinical application
15. Please describe any breakthroughs, new agents, improvements in patient care, etc., based on your ICRA project that were not captured by the preceding questions.
16. If applicable, please share how development of your ICRA project findings into therapies for sickle cell disease might be affected by the recent development of blood malignancies in two patients after treatment with an experimental lentiviral-based treatment.
17. Did your research have an impact on other diseases in addition to sickle cell disease? Yes/no
18. If yes, please describe.

About the ICRA program

19. How did the ICRA grant affect or amplify your research into sickle cell disease?
20. Is there a certain characteristic of the ICRA program that was particularly useful to your research program?

About sickle cell disease research

21. What do you see as the most important breakthrough in sickle cell disease research in the last 10 years?
22. In the future, what type of research funding programs would improve clinical outcomes for patients with sickle cell disease?
23. Upload your most recent biographical sketch.